Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
1.840
+0.050 (2.79%)
At close: Apr 28, 2026, 4:00 PM EDT
1.830
-0.010 (-0.54%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Compass Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
39
Market Cap
331.36M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bicycle Therapeutics | 72.59M |
| Opus Genetics | 14.20M |
| Armata Pharmaceuticals | 4.90M |
| Surrozen | 3.48M |
| Inhibikase Therapeutics | 1.00 |
CMPX News
- 1 day ago - Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 1 day ago - Compass Therapeutics Drops Sharply As Trial Crossover Complicates Survival Data In Bile Duct Cancer Patients - Benzinga
- 1 day ago - Compass Therapeutics Transcript: Study update - Transcripts
- 1 day ago - Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - GlobeNewsWire
- 4 days ago - Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer - GlobeNewsWire
- 7 weeks ago - Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Compass Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference - Transcripts
- 4 months ago - Compass Therapeutics Provides Corporate Update - GlobeNewsWire